Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GUSB | P08236 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47799 | 0.90 | GRIA2 (0.38) | MAPTPLA2G1BATG4BABL1BCR | |
| SCHEMBL47802 | 0.90 | GRIA2 (0.38) | MAPTPLA2G1BATG4BABL1BCR | |
| SCHEMBL17543457 | 0.81 | ATM (0.40) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL29859749 | 0.81 | ATM (0.40) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL17543693 | 0.78 | ATM (0.43) | MAPTKDM4ERAB9AMEN1KMT2A | |
| SCHEMBL8915124 | 0.77 | ATM (0.42) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL17434666 | 0.77 | IDO1 (0.33) | MAPTRAB9ANPC1ATMLMNA | |
| SCHEMBL9234348 | 0.77 | L3MBTL1 (0.37) | MAPTKDM4ETDP1ALDH1A1LMNA | |
| SCHEMBL4276693 | 0.77 | CYP1A2 (0.49) | MAPTABL1BCRRAB9AMEN1 | |
| SCHEMBL10714238 | 0.76 | TDP1 (0.41) | MAPTPLA2G1BATG4BRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0650957-A1 | ANILINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1995-05-03 | — | — | EP | claimed |
| JP-5286909-A | — | — | None | — | — | JP | disclosed |
| EP-2149586-B1 | AMINE EPOXY RESIN CURING AGENT, GAS BARRIER EPOXY RESIN COMPOSITION COMPRISING THE CURING AGENT, COATING AGENT, AND ADHESIVE AGENT FOR LAMINATE | MITSUBISHI GAS CHEMICAL CO (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-9580444-B2 | Polycyclic pyrazolinone derivative and herbicide comprising same as effective component thereof | SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) | 2017-02-28 | — | — | US | disclosed |
| US-20160024110-A1 | POLYCYCLIC PYRAZOLINONE DERIVATIVE AND HERBICIDE COMPRISING SAME AS EFFECTIVE COMPONENT THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| EP-2975040-A1 | POLYCYCLIC PYRAZOLINONE DERIVATIVE AND HERBICIDE COMPRISING SAME AS EFFECTIVE COMPONENT THEREOF | Sagami Chemical Research Institute (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-8128782-B2 | Amine epoxy resin curing agent, gas barrier epoxy resin composition comprising the curing agent, coating agent, and adhesive agent for laminate | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100160494-A1 | AMINE EPOXY RESIN CURING AGENT, GAS BARRIER EPOXY RESIN COMPOSITION COMPRISING THE CURING AGENT, COATING AGENT, AND ADHESIVE AGENT FOR LAMINATE | MITSUBISHI GAS CHEMICAL COMPANY INC. (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2149586-A1 | AMINE EPOXY RESIN CURING AGENT, GAS BARRIER EPOXY RESIN COMPOSITION COMPRISING THE CURING AGENT, COATING AGENT, AND ADHESIVE AGENT FOR LAMINATE | Mitsubishi Gas Chemical Company, Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-0950657-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors | LILLY CO ELI (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0950657-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0650957-A1 | ANILINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1995-05-03 | — | — | EP | disclosed |
| JP-H05286909-A | NITRIBENZENE DERIVATIVE AND ITS PRODUCTION | SUMITOMO CHEM CO LTD | 1993-11-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024110-A1 | POLYCYCLIC PYRAZOLINONE DERIVATIVE AND HERBICIDE COMPRISING SAME AS EFFECTIVE COMPONENT THEREOF | DDT, PDHX, CYP4X1 | MAPT 4308/4885PLA2G1B 3053/4885ATG4B 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.